日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to Davison, G. Comment on "Huijghebaert et al. Does Trypsin Oral Spray (Viruprotect(®)/ColdZyme(®)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union. Int. J. Environ. Res. Public Health 2021, 18, 5066"

回复 Davison, G. 对“Huijghebaert 等人,《胰蛋白酶口腔喷雾剂(Viruprotect®/ColdZyme®)能否预防 COVID-19 和普通感冒,还是会诱发突变?欧盟医疗器械法规的注意事项。《国际环境研究与公共卫生杂志》2021, 18, 5066”一文的评论

Huijghebaert, Suzy; Vanham, Guido; Van Winckel, Myriam; Allegaert, Karel

Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19

新冠疫情期间鼻腔或呼吸道卫生生理盐水药理学要点

Huijghebaert, Suzy; Hoste, Levi; Vanham, Guido

Correction to: Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19

更正:COVID-19 时期鼻腔或呼吸道卫生盐水药理学要点

Huijghebaert, Suzy; Hoste, Levi; Vanham, Guido

Closing schools for SARS-CoV-2: a pragmatic rapid recommendation

因SARS-CoV-2疫情关闭学校:一项务实的快速建议

Bekkering, Geertruida; Delvaux, Nicolas; Vankrunkelsven, Patrik; Toelen, Jaan; Aertgeerts, Sigrid; Crommen, Sofie; Bruyckere, Pedro De; Devisch, Ignaas; Lernout, Tinne; Masschalck, Katrien; Milissen, Nore; Molenberghs, Geert; Pascal, Annelies; Plomteux, Oscar; Raes, Marc; Rans, Lise; Seghers, Alexandra; Sweldens, Lode; Vandenbussche, Jeroen; Vanham, Guido; Wollants, Elke; Aertgeerts, Bert

COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?

COVID-19:感染接种剂量反应关系是否有助于理解疾病严重程度和传播动态的异质性?

Van Damme, Wim; Dahake, Ritwik; van de Pas, Remco; Vanham, Guido; Assefa, Yibeltal

Does Trypsin Oral Spray (Viruprotect(®)/ColdZyme(®)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union

胰蛋白酶口腔喷雾剂(Viruprotect®/ColdZyme®)能否预防新冠病毒和普通感冒,还是会诱发病毒突变?欧盟医疗器械法规中的注意事项

Huijghebaert, Suzy; Vanham, Guido; Van Winckel, Myriam; Allegaert, Karel

The COVID-19 pandemic: diverse contexts; different epidemics-how and why?

COVID-19 大流行:不同的背景;不同的流行病——如何以及为什么?

Van Damme, Wim; Dahake, Ritwik; Delamou, Alexandre; Ingelbeen, Brecht; Wouters, Edwin; Vanham, Guido; van de Pas, Remco; Dossou, Jean-Paul; Ir, Por; Abimbola, Seye; Van der Borght, Stefaan; Narayanan, Devadasan; Bloom, Gerald; Van Engelgem, Ian; Ag Ahmed, Mohamed Ali; Kiendrébéogo, Joël Arthur; Verdonck, Kristien; De Brouwere, Vincent; Bello, Kéfilath; Kloos, Helmut; Aaby, Peter; Kalk, Andreas; Al-Awlaqi, Sameh; Prashanth, N S; Muyembe-Tamfum, Jean-Jacques; Mbala, Placide; Ahuka-Mundeke, Steve; Assefa, Yibeltal

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription

在HIV病毒库极小且持续病毒转录水平极低的患者中,分析治疗中断后病毒载量迅速反弹。

Pannus, Pieter; Rutsaert, Sofie; De Wit, Stéphane; Allard, Sabine D; Vanham, Guido; Cole, Basiel; Nescoi, Coca; Aerts, Joeri; De Spiegelaere, Ward; Tsoumanis, Achilleas; Couttenye, Marie-Madeleine; Herssens, Natacha; De Scheerder, Marie-Angélique; Vandekerckhove, Linos; Florence, Eric

A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa

呼吁加强针对撒哈拉以南非洲弱势群体的、有针对性的、非药物干预措施在新冠肺炎疫情防控方面的证据。

Colebunders, Robert; Siewe Fodjo, Joseph Nelson; Vanham, Guido; Van den Bergh, Rafael

Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix

慢性 HIV-1 感染患者的治疗性疫苗:一项使用 HTI-TriMix 的随机、双盲、安慰剂对照 IIa 期试验

Jong, Wesley de; Leal, Lorna; Buyze, Jozefien; Pannus, Pieter; Guardo, Alberto; Salgado, Maria; Mothe, Beatriz; Molto, Jose; Moron-Lopez, Sara; Gálvez, Cristina; Florence, Eric; Vanham, Guido; Gorp, Eric van; Brander, Christian; Allard, Sabine; Thielemans, Kris; Martinez-Picado, Javier; Plana, Montserrat; García, Felipe; Gruters, Rob A